Roivant Sciences Ltd. - 8-K Filing

Roivant subsidiary Priovant reports positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis (NIU) with plans for sNDA filing in H1 2027. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 21, 2026, 11:06 UTC

Tickers: $ROIV

Read the full article at SEC EDGAR

More Regulatory news

Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
NEXGEL, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
TEREX CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Victory Capital Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
Nano Dimension Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
M-tron Industries, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:56 UTC
M-tron Industries, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:55 UTC